NASDAQ:EVOK Evoke Pharma Q2 2024 Earnings Report $2.89 -0.06 (-2.03%) Closing price 06/13/2025 03:59 PM EasternExtended Trading$2.54 -0.35 (-11.94%) As of 06/13/2025 04:08 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. ProfileEarnings History Evoke Pharma EPS ResultsActual EPS-$0.93Consensus EPS -$0.72Beat/MissMissed by -$0.21One Year Ago EPSN/AEvoke Pharma Revenue ResultsActual Revenue$2.55 millionExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AEvoke Pharma Announcement DetailsQuarterQ2 2024Date8/13/2024TimeBefore Market OpensConference Call DateTuesday, August 13, 2024Conference Call Time7:00AM ETUpcoming EarningsEvoke Pharma's Q2 2025 earnings is scheduled for Monday, August 11, 2025, with a conference call scheduled at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfileConference Call Audio Live Call not available Earnings Conference CallEvoke Pharma Q2 202400:00 / 00:00Speed:1x1.25x1.5x2xPowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Evoke Pharma Earnings HeadlinesBreakeven On The Horizon For Evoke Pharma, Inc. (NASDAQ:EVOK)June 14 at 12:43 PM | finance.yahoo.comEvoke Pharma Inc.June 8, 2025 | wsj.comREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (including the losers!).June 16, 2025 | Weiss Ratings (Ad)Evoke Pharma Reports First Quarter 2025 Financial Results and Provides Business UpdateMay 13, 2025 | globenewswire.comEvoke Pharma Announces Presentation of New Research on Tardive Dyskinesia at Digestive Disease Week 2025April 30, 2025 | nasdaq.comEvoke Pharma to Present New Data Comparing Tardive Dyskinesia Incidence in Continuous vs Intermittent Metoclopramide Use at DDW 2025April 28, 2025 | globenewswire.comSee More Evoke Pharma Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Evoke Pharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Evoke Pharma and other key companies, straight to your email. Email Address About Evoke PharmaEvoke Pharma (NASDAQ:EVOK), a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults. The company markets its products to gastroenterologists, internal medicine specialists, primary care physicians, and select health care providers. Evoke Pharma, Inc. was incorporated in 2007 and is headquartered in Solana Beach, California.View Evoke Pharma ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Broadcom Slides on Solid Earnings, AI Outlook Still StrongFive Below Pops on Strong Earnings, But Rally May StallRed Robin's Comeback: Q1 Earnings Spark Investor HopesOllie’s Q1 Earnings: The Good, the Bad, and What’s NextBroadcom Earnings Preview: AVGO Stock Near Record HighsUlta’s Beautiful Q1 Earnings Report Points to More Gains Aheade.l.f. Beauty Sees Record Surge After Earnings, Rhode Deal Upcoming Earnings Accenture (6/20/2025)FedEx (6/24/2025)Micron Technology (6/25/2025)Paychex (6/25/2025)NIKE (6/26/2025)Bank of America (7/14/2025)Wells Fargo & Company (7/14/2025)JPMorgan Chase & Co. (7/14/2025)Interactive Brokers Group (7/15/2025)América Móvil (7/15/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
